Pashtoon Kasi MD, MS (@pashtoonkasi) ranks #12 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 18 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: CLOVER, MOUNTAINEER, COMMIT. CMS Open Payments lists $122 in 2025 general payments.
At a Glance
- 9 posts naming a trial in 2026
- 4 trials discussed by name
- GI Cancer: US #12 · 18 physicians engaged
- Presented at AACR 2026 in 2026
- CMS Open Payments lists $122 in 2025 general payments.
This Month
What Pashtoon Kasi MD, MS has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Pashtoon Kasi MD, MS
Physicians who reposted Pashtoon Kasi MD, MS’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #12 | — | 18 | 23 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Pashtoon Kasi MD, MS presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- AACR 2026 · PosterFindings from the CLOVER trial (Section 41, Poster 14)Source: @cityofhope on X ↗
Trials Pashtoon Kasi MD, MS Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| CLOVER | 6 | — | Apr 21, 2026 |
| MOUNTAINEER | 1 | — | Jan 12, 2026 |
| COMMIT | 1 | #11 of 14 | Jan 10, 2026 |
| BREAKWATER | 1 | #20 of 22 | Jan 10, 2026 |
Pashtoon Kasi MD, MS on CLOVER
#AACR26 Come to our session 🪧 tomorrow. We call it the CLOVER☘️Trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen 📍2-5 PM 💡Building upon options for our patients with #ColorectalCancer. @OncoAlert @cityofhope https://t.co/PLx60BGKP8
#AACR26 Excited & honored to unveil initial results from the phase-2 CLOVER ☘️ trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen 🏃♂️to our session 🔖 2-5PM 📍Section41🪧Poster14 👇🏽Promising #ctDNA💦📉 MSS #ColorectalCancer @OncoAlert
#AACR26 🔖 2-5 pm today 📍Section 4️⃣1️⃣ 🪧Poster 1️⃣4️⃣ @OncoAlert CLOVER☘️Trial. CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen #ColorectalCancer
Pashtoon Kasi MD, MS on MOUNTAINEER
Good timing with #GI26. 🗞️ Published today📝 @NatureComms Tucatinib➕Trastuzumab Mountaineer 🏔️ regimen HER2 ➕/RAS➖Metastatic colorectal cancer #CRCSM 🔗 https://t.co/XO6l9dp46I 🔑 findings are that responses seen regardless of the method of testing 🔬🆚🧬🆚🩸 @OncoAlert https://t.co/vT2sE0Vyve
Pashtoon Kasi MD, MS on COMMIT
#GI26 The long awaited COMMIT trial. Immunotherapy PDL1⛔️ monotherapy 🆚 FOLFOX➕VEGF⛔️➕PDL1⛔️ 5.3 🆚 24.5 months⁉️ Important insights. While I understand synergy, monotherapy with Atezo is way underperforming compared to prior IO data.📊 @OncoAlert thoughts 💭❓ @NRGonc https://t.co/04KVeVdqj6
Pashtoon Kasi MD, MS on BREAKWATER
#GI26 Nice to have the option of irinotecan chemo backbone as part of the BREAKWATER 💦 regimen for our patients with #BRAFV600E🧬🎯mutant colorectal cancer. 💡Many patients have received oxaliplatin in adjuvant. I also prefer IRI at times since no cumulative issues. @OncoAlert https://t.co/xtvnWUbbVj
Pashtoon Kasi MD, MS’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#ESMO26 Our trial of the #KRAS vaccine 💉presented today alongside concurrent publication in @NatureMedicine! The RAS-revolution continues. Excited about future development, role of ctDNA, and combinatorial strategies. G12D R V S A C & G13D @OncoAlert https://t.co/TbxcUK8Tg3 https://t.co/wnH47HBMMw
🙏🏽 @US_FDA & the scientific community—one of the most common questions I get weekly: When will the “revolutionary” 💊 DaraxonRASib 🧬 be available? My answer: This year—one way or another. You delivered. Patients can’t wait! #Cancer #KRAS https://t.co/Y0BY19mfwL
#ESMO26 Building upon options for our patients with #ColorectalCancer. Our CLOVER☘️Trial CCR5-targeting Leronlimab with Oral chemotherapy & VEGF-inhibitor Enriched Regimen #ctDNA reductions compared to real world+dose response @OncoAlert @cityofhope @benweinbergmd today! https://t.co/gzRHI0kLnB
#AACR26 See our work that challenges so many dogmas about #LiquidBiopsies for cancer. ⚫️Not just DNA🧬, CTCs👇🏽 ⚫️Not just blood, CSF🧠 ⚫️Not just prognostic, predictive🎯CDH17 ⚫️Kinetics🟰📉response CSF cytology was negative ➖ So many💡 🔗https://t.co/58dlVyQssy @OncoAlert https://t.co/92j0OUZ26G
💡What’s cool is the power of #ctDNA on multiple levels in CLOVER☘️Trial 1. It acted as a surrogate to early response 2. We were looking at 2 doses - we saw dose response 3. We were able to collaborate @NateraGenetics to find real world comparator 📈drug development @OncoAlert https://t.co/hAlyvC63Bo
Industry Payments
CMS Open Payments · 2025 general payments
$122 across 3 payments